Ligand Pharmaceuticals Incorporated (LGND)
|52 Week Range||72.57-169.98|
|1y Target Est||-|
|DCF Unlevered||LGND DCF ->|
|DCF Levered||LGND LDCF ->|
|Debt / Equity||34.14%||Neutral|
Upgrades & Downgrades
Latest LGND news
Ligand (LGND) Down 12% Since Last Earnings Report: Can It Rebound?
7 September 2022
Ligand (LGND) reported earnings 30 days ago. What's next for the stock?
Ligand Pharmaceuticals, Inc. (LGND) CEO John Higgins on Q2 2022 Results - Earnings Call Transcript
8 August 2022
Ligand Pharmaceuticals, Inc. (NASDAQ:LGND ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO & Executive Director Matthew Kor...
Ligand Pharmaceuticals (LGND) Misses Q2 Earnings Estimates
8 August 2022
Ligand (LGND) delivered earnings and revenue surprises of -37.04% and 44.62%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ligand to Report Second Quarter Financial Results on August 8
22 July 2022
EMERYVILLE, Calif.--(BUSINESS WIRE)-- #earnings--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report second quarter 2022 financial results after the close of the U.S. financial markets on M...
Sever Your Ties With These 4 Toxic Stocks to Ward Off Losses
5 July 2022
Just like picking up stocks with strong growth potential, pinpointing toxic stocks and abandoning them at the right time hold the key to protecting your portfolio from big losses.
Spot the Red Flags & Sell These 5 Toxic Stocks Right Away
2 June 2022
Detoxify your holdings by steering clear of these five stocks, Alarm.com (ALRM), Ligand (LGND), Radius Global (RADI), ADT Inc. (ADT) and Madison Square (MSGE).
Detoxify Your Holdings by Steering Clear of These 4 Stocks
17 May 2022
Getting rid of fundamentally weak toxic stocks is important to shield your portfolio from losses. MSGE, MTLS, INNV and LGND are a few toxic stocks according to our model that you should dump now.
Ligand (LGND) Q1 Earnings Beat, OmniAb Spin-Off on Track
5 May 2022
Ligand (LGND) reports encouraging first-quarter 2022 numbers by beating estimates on both counts. However, Captisol sales get hurt by lower demand for COVID-19 therapies.
Ligand Pharmaceuticals (LGND) Q1 Earnings Lag Estimates
4 May 2022
Ligand (LGND) delivered earnings and revenue surprises of -4.92% and 33.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Ligand Pharmaceuticals Incorporated (LGND) CEO John Higgins on Q1 2022 Results - Earnings Call Trans...
4 May 2022
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Simon Latimer - Head of Investor Relations John Higgins - CEO Matt Foehr...